271 related articles for article (PubMed ID: 27425755)
1. Simvastatin monotherapy as a potential option for statin-associated muscle symptoms: a case report.
Qu H; Guo M; Kou N; Wu HT; Zhang Y; Gao ZY; Shi DZ
J Clin Pharm Ther; 2016 Oct; 41(5):568-71. PubMed ID: 27425755
[TBL] [Abstract][Full Text] [Related]
2. Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge.
Fung EC; Crook MA
Cardiovasc Ther; 2012 Oct; 30(5):e212-8. PubMed ID: 21884002
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
4. Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.
Golightly LK; Barber GR; Barron MA; Page RL
Drug Metabol Drug Interact; 2013; 28(1):49-58. PubMed ID: 23314530
[TBL] [Abstract][Full Text] [Related]
5. Statin intolerance.
Laufs U; Scharnagl H; März W
Curr Opin Lipidol; 2015 Dec; 26(6):492-501. PubMed ID: 26780003
[TBL] [Abstract][Full Text] [Related]
6. The AKT/mTOR signaling pathway plays a key role in statin-induced myotoxicity.
Bonifacio A; Sanvee GM; Bouitbir J; Krähenbühl S
Biochim Biophys Acta; 2015 Aug; 1853(8):1841-9. PubMed ID: 25913013
[TBL] [Abstract][Full Text] [Related]
7. A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Laaksonen R; Katajamaa M; Päivä H; Sysi-Aho M; Saarinen L; Junni P; Lütjohann D; Smet J; Van Coster R; Seppänen-Laakso T; Lehtimäki T; Soini J; Oresic M
PLoS One; 2006 Dec; 1(1):e97. PubMed ID: 17183729
[TBL] [Abstract][Full Text] [Related]
8. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
[TBL] [Abstract][Full Text] [Related]
9. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
Ambegaonkar BM; Tipping D; Polis AB; Tomassini JE; Tershakovec AM
Atherosclerosis; 2014 Dec; 237(2):829-37. PubMed ID: 25463129
[TBL] [Abstract][Full Text] [Related]
10. [Creatine kinase increase under simvastatin--therapeutic consequences?].
Rasche-Schürmann CC; Picksak G; Stichtenoth DO
Med Monatsschr Pharm; 2008 Jan; 31(1):25-7. PubMed ID: 18522017
[TBL] [Abstract][Full Text] [Related]
11. Clinical features related to statin-associated muscle symptoms.
Ochs-Balcom HM; Nguyen LM; Ma C; Isackson PJ; Luzum JA; Kitzmiller JP; Tarnopolsky M; Weisman M; Christopher-Stine L; Peltier W; Wortmann RL; Vladutiu GD
Muscle Nerve; 2019 May; 59(5):537-543. PubMed ID: 30549046
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
13. Myopathy associated with atorvastatin-ezetimibe combination therapy.
Weffald LA; Flach LA
Pharmacotherapy; 2007 Feb; 27(2):309-11. PubMed ID: 17253923
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
15. Suspected statin-induced respiratory muscle myopathy during long-term inspiratory muscle training in a patient with diaphragmatic paralysis.
Chatham K; Gelder CM; Lines TA; Cahalin LP
Phys Ther; 2009 Mar; 89(3):257-66. PubMed ID: 19147707
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
Taha DA; Zgair A; Lee JB; de Moor CH; Barrett DA; Bruce KD; Sungelo M; Eckel RH; Gershkovich P
Eur J Pharm Sci; 2017 Mar; 100():163-175. PubMed ID: 28104473
[TBL] [Abstract][Full Text] [Related]
17. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.
Young JM; Florkowski CM; Molyneux SL; McEwan RG; Frampton CM; George PM; Scott RS
Am J Cardiol; 2007 Nov; 100(9):1400-3. PubMed ID: 17950797
[TBL] [Abstract][Full Text] [Related]
18. The Risk of Muscular Events Among New Users of Hydrophilic and Lipophilic Statins: an Observational Cohort Study.
Mueller AM; Liakoni E; Schneider C; Burkard T; Jick SS; Krähenbühl S; Meier CR; Spoendlin J
J Gen Intern Med; 2021 Sep; 36(9):2639-2647. PubMed ID: 33751411
[TBL] [Abstract][Full Text] [Related]
19. Low vitamin D does not predict statin associated muscle symptoms but is associated with transient increases in muscle damage and pain.
Taylor BA; Lorson L; White CM; Thompson PD
Atherosclerosis; 2017 Jan; 256():100-104. PubMed ID: 27993387
[TBL] [Abstract][Full Text] [Related]
20. [Statin intolerance].
Graversen CB; Larsen ML; Schmidt EB
Ugeskr Laeger; 2015 Aug; 177(36):. PubMed ID: 26324293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
